Antitumor Potential and Other Emerging Medicinal Properties of Natural Compounds Evandro Fei Fang · Tzi Bun Ng Editors

Total Page:16

File Type:pdf, Size:1020Kb

Antitumor Potential and Other Emerging Medicinal Properties of Natural Compounds Evandro Fei Fang · Tzi Bun Ng Editors Antitumor Potential and Other Emerging Medicinal Properties of Natural Compounds Evandro Fei Fang · Tzi Bun Ng Editors Antitumor Potential and Other Emerging Medicinal Properties of Natural Compounds 1 3 Editors Evandro Fei Fang Tzi Bun Ng Laboratory of Molecular Gerontology School of Biomedical Sciences National Institute on Aging, NIH The Chinese University of Hong Kong Baltimore, MD Hong Kong USA Hong Kong SAR ISBN 978-94-007-6213-8 ISBN 978-94-007-6214-5 (eBook) DOI 10.1007/978-94-007-6214-5 Springer Dordrecht Heidelberg New York London Library of Congress Control Number: 2013932335 © Springer Science+Business Media Dordrecht 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Foreword by Joseph J. Y. Sung The new millennium is characterized by high-tech gadgets such as Facebook, iPad, TV games, but also as an era of genomic medicine. However, residents in our global village are still harried by different incurable and new diseases that threaten human life. Are there any solutions? One way to circumvent the problem is to return to Mother Nature since it is still a main source of drug leads. According to a recent comprehensive review, from around the 1940s to 2010, a total of 175 small compounds with antitumor activity were approved by FDA and similar organi- zations. Among them, 74.8 % were other than synthetic compounds and 48.6 % were natural products and their derivatives [2]. However, good reference books in this field are scarce. Therefore, the book ‘Health Cornucopia: The Emerging Medicinal Properties of Natural Compounds’ arrives at the most opportune moment. This repertoire of promising medicinal components encompasses a variety of molecules ranging from large proteins to small compounds. Molecules on this list appear sequentially as lectins, ribonucleases, ribosome inactivating proteins, pro- tease inhibitors, and a vast diversity of small compounds (such as triterpenoids). In order to enlighten readers on the medicinal efficacies of the components at the cellular and molecular levels, the chapters in each part of this book not only place a focus on the stirring history of discovery of the components, but also present a detailed description of the molecular mechanisms and clinical research stud- ies wherever possible. Examples include MAP30, BBIC, acetaldehyde, rapamy- cin, and others. The book also contains information on some new hot research areas which are related but not limited to cancer research, such as the strategy of exploiting autophagy for neurodegenerative diseases, the crosstalk between apop- tosis and autophagy, and the prolongation of life span by employing natural com- pounds. Moreover, the book does not restrict the origin of natural compounds to plants, but extends it to bacteria, fungi, and animals. For instance, there are chap- ters on animal lectins, lectins of marine organisms, and plant lectins, which render the library of drug candidates more vivid. Ethnomedicine is emerging as a new trend globally. Though a dominant con- tribution to human health in the old times, it was displaced by modern medicine and has faded away for many years. However, it is now enjoying a revival as many diseases can be alleviated by ‘complementary medicine’. Traditional Chinese v vi Foreword by Joseph J. Y. Sung medicine (TCM), which constitutes an important part of ethnomedicine, has been credited with some efficacy during its long history of practice. Eminent examples comprise arsenic trioxide (a therapy for human acute promyelocytic leukaemia), artemisinin from Artemisia annua (exhibiting anti-malaria activity), bitter melon (Momordica charantia), and Cordyceps sinensis which manifests many exploita- ble pharmacological activities. Two chapters in this book are focused on the recent progress of research on medicinal compounds in the bitter melon. There is also a chapter on high-throughput screening for discovery of TCM-based drugs which may provide a guideline for future drug evaluation. The research accomplishments alluded to in these chapters as well as elsewhere furnish a scientific basis for the application of TCM and other ethnomedicine. The editors of this book are Prof. T. B. Ng who is a professor at the Chinese University of Hong Kong and Dr. Evandro Fei Fang who is a brilliant young sci- entist in the field. I am confident that this book will provide comprehensive and useful information to researchers in the fields of cancer research, pharmacognosy, drug discovery, preventive medicine, plant nutrition, and others. For undergradu- ate and graduate students with a curiosity about natural products with medicinal activity, I recommend you this book as a valuable guide to the fascinating, rapidly evolving, and rewarding scientific genre. Joseph J. Y. Sung MD, Ph.D. Mok Hing Yiu Professor of Medicine President and Vice Chancellor The Chinese University of Hong Kong Shatin, Hong Kong Foreword by Rob Verpoorte The most important human heritage: our knowledge of the use of plants as a resource for drug development The most important human heritage is the knowledge of nature, allowing us to survive in a hostile environment. The use of plants is probably the most impor- tant of this heritage. The knowledge of plants that serve us as food, fuel, shelter, medicines, dyes, fibers, etc., is the basis of our life! At present we use some 30 species for our staple food, about 100 for their fruits and also about 100 as veg- etables. It is estimated that some 30,000–70,000 species are used for medicinal purposes [1], of which at present some 100 are used for the production of pure compounds used in western medicine. Much of the latter group originate from the Mediterranean/Middle East area and were already described in old Egyptian, Persian, Greek, Roman, and Arab manuscripts. In the nineteenth and twentieth centuries these medicines were further developed leading to the use of pure com- pounds and later even to derivatives or synthetic analogues with improved pharma- cological properties. Despite the high score of active compounds from studies of a limited num- ber of medicinal plants, so far most medicinal plants have hardly been studied in-depth for potential novel medicines. This untapped reservoir of traditional knowledge is a very promising resource for drug development and our major challenge is to develop efficient ways to tap this human heritage for the benefit of humanity. The statistics on the novel drugs developed in the past three decades show clearly the importance of nature as a source for drug development, almost half of all novel small-molecule drugs are natural products or natural products derived compounds [2]. In the last three decades drug development has followed two major strategies. One is rational drug design and is based on the knowledge of targets. This means receptors or enzymes involved in diseases. In this approach, computational meth- ods were developed to design medicines based on the knowledge of stereochemis- try of targets. The limitation of this approach is that no novel modes of action are found, only when novel targets are discovered novel drugs can be developed. The other approach is high throughput screening (HTS), in which large numbers of compounds are measured in fast micro/nano scale bioassays, allowing thousands vii viii Foreword by Rob Verpoorte of compounds to be tested per day. Again this approach is based on the knowledge of targets, and thus has the same limitation of the other approach, one may find novel active structures, but still for the same target. Both approaches are based on the “single target-single compound” paradigm. However, drug development is stalling using these approaches, only novel tar- gets may lead to novel first-in-class medicines. Moreover, except for infectious and parasitic diseases, where an exogenous organism has to be eliminated, most diseases are multifactorial and concern endogenous processes, e.g., cancer and chronic inflammatory diseases. Chances that a single target drug will cure such diseases are small. The success in treating HIV-infected patients is due to the use of multidrug treatments. But if developing a single molecule drug is difficult, two- or even multi-component medicines are exponentially more difficult. At least it seems time for a paradigm shift to develop the next generation of medicines.
Recommended publications
  • PS CV Comp 050917
    CURRICULUM VITAE NAME: Pamela Mary Stanley (nee Fetherstonhaugh) Lab Homepage http://www.einstein.yu.edu/departments/cellbiology/faculty/stanley/home/ NATIONALITY: Australian/American EDUCATION: l965-l967 Bachelor of Science University of Melbourne, Australia Majored in Biochemistry and Microbiology l968 B. Sc. Hons., Walter and Eliza Hall Institute, Melbourne, Australia Commonwealth Post-graduate Award Advisor: Gordon L. Ada Thesis: Tolerance to Foreign Erythrocytes Using Antigen-Containing Extracts of the Erythrocyte Membrane. l969-l972 Research for degree of Doctor of Philosophy in the Department of Microbiology, University of Melbourne, Australia Commonwealth Post-graduate Award Advisor: Professor David O. White Thesis: Influenza Virus Proteins l972-l975 Postdoctoral Fellow of the Medical Research Council of Canada in the Department of Medical Genetics, University of Toronto, Canada Advisor: Dr. Louis Siminovitch Postdoctoral Fellowship from the Medical Research Council of Canada Topic: The Isolation and Characterization of Lectin Resistant Chinese Hamster Ovary Cells. POSITIONS HELD: l976 Research Associate Department of Medical Genetics University of Toronto Toronto, Ontario, Canada l977-1982 Assistant Professor Dept. of Cell Biology Albert Einstein College of Medicine Bronx, New York 1982-1986 Associate Professor Dept. of Cell Biology Albert Einstein College of Medicine Bronx, New York 1986 Professor Department of Cell Biology Albert Einstein College of Medicine Bronx, New York 1994-2007 Director Training Program in Cell & Molecular Biology, Biochemistry & Genetics, NIGMS 1 1988-2012 Program leader Membrane Molecular Biology Albert Einstein Cancer Center 2002- Associate Director for Laboratory Research Albert Einstein NCI Cancer Center 2007- Horace W. Goldsmith Foundation Chair. HONORS: Dunlop Prize for First Place in Biochemistry (1966 and 1967) Aust.
    [Show full text]
  • Evolutionary Genomics of a Plastic Life History Trait: Galaxias Maculatus Amphidromous and Resident Populations
    EVOLUTIONARY GENOMICS OF A PLASTIC LIFE HISTORY TRAIT: GALAXIAS MACULATUS AMPHIDROMOUS AND RESIDENT POPULATIONS by María Lisette Delgado Aquije Submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy at Dalhousie University Halifax, Nova Scotia August 2021 Dalhousie University is located in Mi'kma'ki, the ancestral and unceded territory of the Mi'kmaq. We are all Treaty people. © Copyright by María Lisette Delgado Aquije, 2021 I dedicate this work to my parents, María and José, my brothers JR and Eduardo for their unconditional love and support and for always encouraging me to pursue my dreams, and to my grandparents Victoria, Estela, Jesús, and Pepe whose example of perseverance and hard work allowed me to reach this point. ii TABLE OF CONTENTS LIST OF TABLES ............................................................................................................ vii LIST OF FIGURES ........................................................................................................... ix ABSTRACT ...................................................................................................................... xii LIST OF ABBREVIATION USED ................................................................................ xiii ACKNOWLEDGMENTS ................................................................................................ xv CHAPTER 1. INTRODUCTION ....................................................................................... 1 1.1 Galaxias maculatus ..................................................................................................
    [Show full text]
  • GLYCO 21 XXI International Symposium on Glycoconjugates
    GLYCO 21 XXI International Symposium on Glycoconjugates Abstracts August 21-26, 2011 Vienna, Austria Glycoconj J (2011) 28: 197–36 9 Organising Committee Erika Staudacher (Austria) Leopold März (Austria) Günter Allmaier (Austria) Lothar Brecker (Austria) Josef Glössl (Austria) Hanspeter Kählig (Austria) Paul Kosma (Austria) Lukas Mach (Austria) Paul Messner (Austria) Walther Schmid (Austria) Igor Tvaroška (Slovakia) Reinhard Vlasak (Austria) Iain Wilson (Austria) Scientifi c Program Committee Iain Wilson (Austria) Paul Messner (Austria) Günter Allmaier (Austria) Reginald Bittner (Austria) Paul Kosma (Austria) Eva Stöger (Austria) Graham Warren (Austria) John Hanover (USA; nominated by the Society for Glycobiology) Kelly ten Hagen (USA; nominated by the Society for Glycobiology) supported in abstract selection by Michael Duchêne (Austria) Catherine Merry (UK) Tadashi Suzuki (Japan) Abstracts of the 21st International Symposium on Glycoconjugates The International Glycoconjugate Organisation Gerald W. Hart, President Leopold März, President-elect Paul Gleeson, Immediate Past-president Sandro Sonnino, Secretary Thierry Hennet, Treasurer National Representatives Pedro Bonay (Spain) to replace Angelo Reglero Nicolai Bovin (Russia) Jin Won Cho (Korea) Henrik Clausen (Denmark) Anne Dell (UK) Jukka Finne (Finland) Paul Gleeson (Australia) Jianxin Gu (China) Gerald Hart (USA) Thierry Hennet (Switzerland) Jim Jamieson (Canada) Gordan Lauc (Croatia) Hakon Leffl er (Sweden) Jean-Claude Michalski (France) Werner Reutter (Germany) Sandro Sonnino (Italy) Avadhesha Surolia (India) Ken Kitajima (Japan) Maciej Ugorski (Poland) Johannes F.G. Vliegenthart (The Netherlands) Iain Wilson (Austria) to replace Leopold März Albert M. Wu (Taiwan) Lode Wyns (Belgium) Yehiel Zick (Israel) Glycoconj J (2011) 28: 197–369 Past Presidents Eugene. A. Davidson (USA) Alan B. Foster (UK) Paul Gleeson (Australia) Mary Catherine Glick (USA) Colin Hughes (UK) Roger W.
    [Show full text]
  • Carbohydrate-De¢Cient Glycoprotein Syndrome Type II
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1455 (1999) 179^192 www.elsevier.com/locate/bba Review Carbohydrate-de¢cient glycoprotein syndrome type II Harry Schachter a;*, Jaak Jaeken b a Department of Biochemistry, University of Toronto Medical School, and Department of Structural Biology and Biochemistry, Hospital for Sick Children, 555 University Avenue, Toronto, Ont. M5G 1X8, Canada b Center for Metabolic Disease, University of Leuven, Leuven, Belgium Received 8 February 1999; accepted 3 May 1999 Abstract The carbohydrate-deficient glycoprotein syndromes (CDGS) are a group of autosomal recessive multisystemic diseases characterized by defective glycosylation of N-glycans. This review describes recent findings on two patients with CDGS type II. In contrast to CDGS type I, the type II patients show a more severe psychomotor retardation, no peripheral neuropathy and a normal cerebellum. The CDGS type II serum transferrin isoelectric focusing pattern shows a large amount (95%) of disialotransferrin in which each of the two glycosylation sites is occupied by a truncated monosialo-monoantennary N-glycan. Fine structure analysis of this glycan suggested a defect in the Golgi enzyme UDP-GlcNAc:K-6-D-mannoside L-1,2-N-acetylglucosaminyltransferase II (GnT II; EC 2.4.1.143) which catalyzes an essential step in the biosynthetic pathway leading from hybrid to complex N-glycans. GnT II activity is reduced by over 98% in fibroblast and mononuclear cell extracts from the CDGS type II patients. Direct sequencing of the GnT II coding region from the two patients identified two point mutations in the catalytic domain of GnT II, S290F (TCC to TTC) and H262R (CAC to CGC).
    [Show full text]
  • Department of the Interior
    Vol. 77 Monday, No. 63 April 2, 2012 Part II Department of the Interior Fish and Wildlife Service 50 CFR Part 17 Endangered and Threatened Wildlife and Plants; 12-Month Finding on a Petition to List the San Francisco Bay-Delta Population of the Longfin Smelt as Endangered or Threatened; Proposed Rule VerDate Mar<15>2010 19:41 Mar 30, 2012 Jkt 226001 PO 00000 Frm 00001 Fmt 4717 Sfmt 4717 E:\FR\FM\02APP2.SGM 02APP2 mstockstill on DSK4VPTVN1PROD with PROPOSALS2 19756 Federal Register / Vol. 77, No. 63 / Monday, April 2, 2012 / Proposed Rules DEPARTMENT OF THE INTERIOR FOR FURTHER INFORMATION CONTACT: Furthermore, we found the Sacramento- Mike Chotkowski, Field Supervisor, San San Joaquin River estuary population of Fish and Wildlife Service Francisco Bay-Delta Fish and Wildlife longfin smelt was not a distinct Office (see ADDRESSES); by telephone at population segment (DPS) because we 50 CFR Part 17 916–930–5603; or by facsimile at 916– determined that the population was not 930–5654 mailto:. If you use a biologically significant to the species as [Docket No. FWS–R8–ES–2008–0045: telecommunications device for the deaf a whole, and did not appear to be 4500030113] (TDD), please call the Federal sufficiently reproductively isolated. Endangered and Threatened Wildlife Information Relay Service (FIRS) at On August 8, 2007, we received a and Plants; 12-Month Finding on a 800–877–8339. petition from the Bay Institute, the Petition to List the San Francisco Bay- SUPPLEMENTARY INFORMATION: Center for Biological Diversity, and the Delta Population of the Longfin Smelt Background Natural Resources Defense Council to as Endangered or Threatened list the San Francisco Bay-Delta Section 4(b)(3)(B) of the Endangered (hereafter referred to as the Bay-Delta) AGENCY: Fish and Wildlife Service, Species Act of 1973, as amended (Act) population of the longfin smelt as a DPS Interior.
    [Show full text]
  • ''Glycosylation Diseases: Quo Vadis?''
    ”Glycosylation diseases: Quo vadis?” Harry Schachter, Hudson Freeze To cite this version: Harry Schachter, Hudson Freeze. ”Glycosylation diseases: Quo vadis?”. Biochimica et Biophysica Acta - Molecular Basis of Disease, Elsevier, 2009, 1792 (9), pp.925. 10.1016/j.bbadis.2008.11.002. hal-00562879 HAL Id: hal-00562879 https://hal.archives-ouvertes.fr/hal-00562879 Submitted on 4 Feb 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ÔØ ÅÒÙ×Ö ÔØ ”Glycosylation diseases: Quo vadis?” Harry Schachter, Hudson Freeze PII: S0925-4439(08)00227-5 DOI: doi: 10.1016/j.bbadis.2008.11.002 Reference: BBADIS 62892 To appear in: BBA - Molecular Basis of Disease Received date: 11 September 2008 Revised date: 3 November 2008 Accepted date: 6 November 2008 Please cite this article as: Harry Schachter, Hudson Freeze, ”Glycosylation diseases: Quo vadis?”, BBA - Molecular Basis of Disease (2008), doi: 10.1016/j.bbadis.2008.11.002 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form.
    [Show full text]
  • 100 Years of Biochemistry at the University of Toronto – Marian A
    Bulletin The Canadian Society of Biochemistry, Molecular & Cellular Biology La Société canadienne de biochemie, de biologie moléculaire et cellulaire ISSN 1197-6578/2007 2007 www.csbmcb.ca Bulletin The Canadian Society of Biochemistry, Molecular & Cellular Biology La Société canadienne de biochemie, de biologie moléculaire et cellulaire 2007 www.csbmcb.ca 2 CSMCB/SCBBMC BULLETIN 2007 FRONT COVER IMAGES: Illustration by Martin Krzywinski, Scientist (Mapping), Canada’s Michael Smith Genome Sciences Centre CSMCB/SCBBMC BULLETIN 2007 3 Contents CSBMCB Board for 2007-2008................................................................................................4 CSBMCB President’s Report...................................................................................................5 Incoming Members of the CSBMCB Executive Board 2006-2007....................................8 Laura Frost, Vice-President; Jean-Pierre Perreault, Councillor; David Williams, Councillor Minutes of the 50th CSBMCB Annual General Meeting ..................................................12 CSBMCB/SCBBMC Financial Statement.............................................................................15 The 50th Annual Meeting of the CSBMCB.........................................................................17 Poster and travel award recipients for the 2007 CSBMCB Meeting .............................19 Scenes from the 2007 CSBMCB Meeting ............................................................................21 Program for the 51st Annual Meeting of the
    [Show full text]
  • Alternative Methods for Assessing Habitat Quality in Freshwater Systems
    Alternative methods for assessing habitat quality in freshwater systems Item Type Thesis or dissertation Authors Mauvisseau, Quentin Citation Mauvisseau, Q 2020, 'Alternative methods for assessing habitat quality in freshwater systems', PhD thesis, University of Derby, Derby Publisher University of Derby Download date 28/09/2021 22:40:52 Link to Item http://hdl.handle.net/10545/625067 University of Derby Alternative methods for assessing habitat quality in freshwater systems Quentin Mauvisseau Doctor of Philosophy 2020 THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK 2 CONTENTS Figures............................................................................................................................................. 7 Tables .............................................................................................................................................. 9 Appendices .................................................................................................................................... 11 Abbreviations ................................................................................................................................ 12 Preface........................................................................................................................................... 14 Abstract ......................................................................................................................................... 17 Acknowledgment .........................................................................................................................
    [Show full text]
  • Calendar 2008-2009
    University of Toronto School of Graduate Studies 2008 / 2009 Calendar Graduate Programs: Web Site: Student Services at SGS: For admission and application www.sgs.utoronto.ca Telephone: (416) 978-6614 information, contact the graduate unit Fax: (416) 978-4367 directly. Contact information and Web E-mail: site addresses are listed in each unit's [email protected] entry. [email protected] 63/65 St. George Street, Toronto, Ontario, Canada, M5S 2Z9 Mission Statement Dean’s Welcome The mission of the School of Graduate Studies I am delighted to welcome you to the many graduate is to promote excellence in graduate education and communities of the University of Toronto. We are proud of research University-wide and ensure consistency and our accomplishments as a centre for graduate education high standards across the divisions. Sharing respon- that integrates advanced scholarship and research into sibility for graduate studies with graduate units and every degree program. Please use this site to learn more divisions, and operating through a system of collegial about the excellent programs we offer. governance, consultation and decanal leadership, Here at the largest graduate school in Canada, over SGS defines and administers university-wide regula- 13,000 graduate students are studying in an extraordi- tions for graduate education. nary range of scholarly fields. The diversity of our depart- SGS also provides expertise, advice and information; ments, centres, and institutes means that the focus and oversees the design and delivery of programs; organizes expertise that you seek is very likely to be found within reviews and develops performance standards; supports the graduate offerings at U of T.
    [Show full text]
  • Glycoproteins: Biosynthesis, Structure and Biological Functions
    GLYCOPROTEINS: BIOSYNTHESIS, STRUCTURE AND BIOLOGICAL FUNCTIONS by Wesley F. Zandberg B.Sc. (Hons.), Trinity Western University 2002 THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY In the Department of Chemistry © Wesley F. Zandberg 2010 SIMON FRASER UNIVERSITY Fall 2010 All rights reserved. However, in accordance with the Copyright Act of Canada, this work may be reproduced, without authorization, under the conditions for Fair Dealing. Therefore, limited reproduction of this work for the purposes of private study, research, criticism, review and news reporting is likely to be in accordance with the law, particularly if cited appropriately. APPROVAL Name: Wesley F. Zandberg Degree: Ph.D Title of Thesis: Glycoproteins: Biosynthesis, structure and biological functions Examining Committee: Chair: Dr. Hua-Zhong (Hogan) Yu Professor, Department of Chemistry ______________________________________ Dr. B. Mario Pinto Professor, Senior Supervisor ______________________________________ Dr. Vance E. Williams Associate Professor, Committee Member ______________________________________ Dr. Margo M. Moore Professor, Committee Member ______________________________________ Robert N. Young Professor, Internal Examiner ______________________________________ Dr. Harry Schachter Professor Emeritus, Department of Biochemistry, University of Toronto, External examiner ______________________________________ Date Defended/Approved: November 25 2010 ii Declaration of Partial Copyright Licence The author, whose copyright is declared on the title page of this work, has granted to Simon Fraser University the right to lend this thesis, project or extended essay to users of the Simon Fraser University Library, and to make partial or single copies only for such users or in response to a request from the library of any other university, or other educational institution, on its own behalf or for one of its users.
    [Show full text]
  • An Annotated List of the Marine and Brackish-Water Ichthyofauna of Aniva Bay (Sea of Okhotsk, Sakhalin Island): 1
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/327079021 An Annotated List of the Marine and Brackish-Water Ichthyofauna of Aniva Bay (Sea of Okhotsk, Sakhalin Island): 1. Petromyzontidae−Agonidae Families Article in Journal of Ichthyology · August 2018 CITATIONS READS 0 59 4 authors: Yury Valentinovich Dyldin A. M. Orlov Tomsk State University Russian Federal Research Institute of Fisheries and Oceanography 22 PUBLICATIONS 41 CITATIONS 530 PUBLICATIONS 1,341 CITATIONS SEE PROFILE SEE PROFILE Lubomir Hanel Vladimir Romanov Charles University in Prague Tomsk State University 45 PUBLICATIONS 158 CITATIONS 15 PUBLICATIONS 18 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: The study of the population structure of Greenland halibut (Reinhardtius hippoglossoides) in Russian waters of the Barents, Okhotsk, Bering and Laptev Seas, using otolith shape analysis methods. View project Taxonomy, microevolution, distribution and biology of morid cods Antimora spp. (Moridae, Gadiformes, Teleostei) of the world’s oceans View project All content following this page was uploaded by Yury Valentinovich Dyldin on 17 August 2018. The user has requested enhancement of the downloaded file. ISSN 0032-9452, Journal of Ichthyology, 2018, Vol. 58, No. 4, pp. 473–501. © Pleiades Publishing, Ltd., 2018. Original Russian Text © Yu.V. Dyldin, A.M. Orlov, A.Ya. Velikanov, S.S. Makeev, V.I. Romanov, L. Hanel, 2018, published in Voprosy Ikhtiologii, 2018, Vol. 58, No. 4, p. 421. An Annotated List of the Marine and Brackish-Water Ichthyofauna of Aniva Bay (Sea of Okhotsk, Sakhalin Island): 1.
    [Show full text]
  • The Clinical Relevance of Glycobiology
    The clinical relevance of glycobiology Harry Schachter J Clin Invest. 2001;108(11):1579-1582. https://doi.org/10.1172/JCI14498. Commentary The study of protein-bound glycans dates back to the 19th century (1). Until recently these macromolecules have played second fiddle to their cousins, the nucleic acids and proteins. This is not surprising in view of the stunning advances during the second half of the 20th century in the DNA-RNA-protein paradigm, which Francis Crick called the Central Dogma. Since information transfer is a key ingredient of this dogma, it is relevant to point out that the diversity of linkages and branching patterns between monomer building blocks confers on carbohydrates the ability to carry an enormous amount of information in very compact structures (2). These structures therefore carry “more information bang for the buck” than do the other, simpler polymers. The cell surface is covered with protein- and lipid-bound glycans. These structures vary significantly between cell types and at different stages of mammalian development and probably play important roles in the interaction of a cell with its cellular and fluid environment (3–5). Glycoproteins and proteoglycans are essential for normal development in mice (6–16), Drosophila melanogaster (17–20), and Caenorhabditis elegans (18, 21–26). Table 1 lists mice with null mutations in genes required for glycosylation; other null mutant mice are described in reviews by Stanley (9) and Varki and Marth (11). In spite of all the evidence showing the importance of glycans for metazoan […] Find the latest version: https://jci.me/14498/pdf The clinical relevance of glycobiology Commentary Harry Schachter See related articles, pages 1613–1619 and 1687–1695.
    [Show full text]